[The currently accepted pathophysiological model underlying surgical management of Parkinson disease].
Among all the extrapiramidal movement disorders Parkinson's disease (PD) is the one most often submitted to neurosurgical treatment. Technical advances in neurosurgery, neuroimaging and neurophysiology, as well as shortcomings of chronic Levodopa medication (i.e. on/off fluctuations, violent dyskinesia and painful dystonia) have greatly contributed to the renewed interest in the surgical treatment of PD. The attainment of a better understanding of the basal ganglia function and of PD pathophysiology has also encouraged centers to treat Parkinson's disease in recent years. This article presents the current model of PD and the rationale for using GPi, thalamus and STN as target sites in stereotactic surgery.
Sobstyl
Michał
M
Kliniki Neurochirurgii CMKP, Wojewódzkiego Szpitala Bródnowskiego w Warszawie.
Zabek
Mirosław
M
Koziara
Henryk
H
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001479:Basal Ganglia / Q000503:physiopathology / Q000601:surgery; D001480:Basal Ganglia Diseases / Q000503:physiopathology / Q000601:surgery; D004599:Electric Stimulation Therapy / Q000295:instrumentation; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D019635:Neurosurgical Procedures / Q000379:methods*; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology* / Q000601:surgery*; D016634:Radiosurgery / Q000295:instrumentation; D009435:Synaptic Transmission / Q000502:physiology; D013788:Thalamus / Q000601:surgery*; D020651:Ventral Thalamic Nuclei / Q000503:physiopathology / Q000601:surgery
D000978:Antiparkinson Agents; D007980:Levodopa